treatment for myotonic dystrophy

Compound frees a crucial protein from a cellular trap in mice with MMD1; treatment prospects 'bright'

posted on July 17, 2009 - 4:03pm
Researchers at the University of Rochester (N.Y.) Wellstone Muscular Dystrophy Cooperative Research Center have identified a compound that has the potential to be developed into a treatment for type 1 myotonic dystrophy (MMD1, or DM1). The compound, dubbed CAG25, is an "antisense oligonucleotide," a type of construct that's been used to block disease-causing genetic instructions in laboratory...

New content is being added every day. Please check back again.